Details of the Drug

General Information of Drug (ID: DM4CWNN)

Drug Name
AVT02
Synonyms adalimumab biosimilar
Indication
Disease Entry ICD 11 Status REF
Plaque psoriasis EA90.0 Phase 3 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DI0CX8

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Plaque psoriasis
ICD Disease Classification EA90.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tumor necrosis factor (TNF) DTT TNF 8.51E-01 0.05 0.27
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT03849404) A Multicenter, Double-blind, Randomized, Parallel-group, Active Control Study to Compare the Efficacy, Safety, and Immunogenicity of AVT02 Versus Humira? in Patients With Moderate-to-Severe Chronic Plaque Psoriasis (ALVOPAD PS). U.S.National Institutes of Health.
2 AVT02: An Adalimumab Biosimilar. Clin Drug Investig. 2022 Oct;42(10):875-878.